Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA
Links shared publicly online about this topic.
- 808total visits
Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA
View full resource at drugs.com
Tags: Bipolar Disorder, Schizophrenia, Psychotic Disorder, Disease and Condition, Drug, Pharma, Nature
Most Recently Shared on October 11, 2010 at 11:11 pm By:
Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA: MOUNTAIN VIEW, C... http://bit.ly/drBmdK #drug
FDA Issues Complete Response Letter to NDA for Adasuve - MPR
empr.com — “Alexza Pharmaceuticals announced that it has received a complete response letter from the FDA regarding its New Drug Application (NDA) for Adasuve (Staccato loxapine) inhalation powder, 5mg and 10mg, for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.” View full resource at empr.com
Most Recently Shared on May 7, 2012 at 3:35 pm By:
FDA Issues Complete Response Letter to NDA for #Adasuve #Alexza #loxapine #inhalation #agitation http://t.co/UloQRAV8
Alexza Pharmaceuticals " Investor Relations - RSS Content
phx.corporate-ir.net — “Alexza Pharmaceuticals Welcome” View full resource at phx.corporate-ir.net
Most Recently Shared on October 11, 2010 at 1:25 pm By:
eyeonfda Pharma and Health Lawyer
Alexza Gets Complete Response Letter for AZ-004 (Staccato(R) Loxapine) (for agitation in bipolar/schizophrenia pts) NDA http://ow.ly/2RBNW
Advertisement
